Suchergebnisse

Major depression (MD) is a major cause of disability and a significant public health problem due to strong physical and mental impairment, possible complications for patients (including suicides), serious social and working problems to the patient and his/her family. We provide an overview of the social cost of Major depression worldwide. We conducted a systematic literature review. Two search engines were queried. Screening of records and summary of evidence was performed by two researchers blindly. The review was conducted in accordance with the standards of the PRISMA guidelines.

Twenty studies met the inclusion criteria. Despite the heterogeneity in terms of population, setting and estimation techniques, the studies showed that the largest share of the burden of disease is represented by indirect costs. Among direct healthcare costs, inpatient care represents the most significant item, followed by outpatient care. The average total direct cost of depression ranges between €508 and €24 069, depending on the jurisdiction where the analysis was run and the range of cost items included. Indirect costs range between €1963 and €27 364.

Evidence on the cost of MD in some countries is currently lacking. A deeper understanding of the drivers of the economic burden of disease is a crucial starting point for studies concerned with the cost-effectiveness of new treatment strategies.

AbstractThis study examines spatial disparities and associations between the social deprivation index (SDI) and Type 2 Diabetes, Dementia, and Heart Failure in Italy's Lazio Region. The primary goal is to assess how social deprivation impacts health inequalities by analysing SDI-disease correlations. This retrospective study uses 2020 socioeconomic data and 2021 epidemiological indicators in Lazio Region, Italy. The SDI, constructed following established guidelines, measures social deprivation. Statistical tools, including regression models, Moran's I test, and LISA techniques, are used to analyse spatial patterns. Utilizing a retrospective approach, we merge 2020 socioeconomic and 2021 epidemiological data for analysis. The SDI is computed using established methods. Spatial disparities are explored through regression models, Moran's I test, and LISA techniques. The study reveals significant disparities in disease incidence. District V in Rome exhibits high Type 2 Diabetes (113.75/1000) and Heart Failure (37.98/1000) rates, while Marcetelli has elevated Dementia incidence (19.74). Southern municipalities face high unemployment (up to 25%), whereas bordering areas have higher education levels (30–60%). Disease hotspots emerge in Rome and centre-north municipalities, aligning with social deprivation patterns. Regression models confirm the link between disease incidence and socioeconomic indicators. SDI ranges from − 1.31 to + 10.01. This study underscores a correlation between social deprivation and disease incidence. Further national-level research is essential to deepen our understanding of how social deprivation influences health outcomes, with potential implications for addressing health disparities both regionally and nationally.

Assessments of new health technologies in Europe are often made at the hospital level. However, the guidelines for health technology assessment (HTA), e.g. the EUnetHTA Core Model, are produced by national HTA organizations and focus on decision-making at the national level. This paper describes the results of an interview study with European hospital managers about their need for information when deciding about investments in new treatments. The study is part of the AdHopHTA project. Face-to-face, structured interviews were conducted with 53 hospital managers from nine European countries. The hospital managers identified the clinical, economic, safety and organizational aspects of new treatments as being the most relevant for decision-making. With regard to economic aspects, the hospital managers typically had a narrower focus on budget impact and reimbursement. In addition to the information included in traditional HTAs, hospital managers sometimes needed information on the political and strategic aspects of new treatments, in particular the relationship between the treatment and the strategic goals of the hospital. If further studies are able to verify our results, guidelines for hospital-based HTA should be altered to reflect the information needs of hospital managers when deciding about investments in new treatments.

Health systems around the world seek to address patients' unmet health needs for a range of acute and chronic diseases. Simultaneously, governments strive to keep healthcare spending sustainable, while providing equal access to high-quality care. This has fuelled debate around what constitutes a valuable healthcare intervention in a health system and the corollary consideration of what governments are willing to pay for a certain health intervention. Until recently, the value of information in general, and the value of diagnostic information (VODI) specifically, was not part of the discussion.However, investment in diagnostic information can be a key development as information may guide more effective and efficient healthcare and help maintain an affordable health system. This paper therefore explores ways to best define, evaluate, and reward the value created from diagnostics in healthcare and how to include these value considerations in decision-making processes for diagnostics. The authors ultimately call for a holistic VODI framework that accounts for the full range of potential benefits of diagnostic testing, beyond the traditional clinical and health economic domains, and that is essential to recognise, measure, and fully leverage the benefits of diagnostics for patients, health systems, and society.